Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors

Vincent Vandecaveye(KU Leuven), Christophe M. Deroose(KU Leuven), Felix M. Mottaghy(College Board), Frederik De Keyzer(KU Leuven), Sofie Van Binnebeek(KU Leuven), Kristiaan Nackaerts(Heidelberg University), Raphaëla C. Dresen(Maastricht University Medical Centre), Elin Pauwels(KU Leuven), Ragna Vanslembrouck(KU Leuven), Kristof Baete(KU Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)
Radiology Imaging Cancer
May 1, 2022
10.1148/rycan.210095
Cited by 7

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k